Table 4.
Summary of treatment outcomes of all pooled patients.
| Characteristics | Value |
|---|---|
| Post-Surgical Complications (n = 555) | No. (%) |
| Cerebrospinal Fluid Leak | 36 (6.5%) |
| Transient | 88 (15.9%) |
| Cranial Nerve Neuropathies | 58 (10.5%) |
| Meningitis/Brain Abscess | 16 (2.9%) |
| Aphasia | 4 (0.7%) |
| Hearing Impairment | 4 (0.7%) |
| Others | 6 (1.1%) |
| Persistent | 59 (10.6%) |
| Cranial Nerve Neuropathies | 37 (6.7%) |
| Intracerebral Hemorrhage | 8 (1.4%) |
| Ischemic Stroke | 4 (0.7%) |
| Hearing Loss | 2 (0.4%) |
| Pulmonary Embolism | 2 (0.4%) |
| Sepsis | 2 (0.4%) |
| Others | 4 (0.7%) |
| Severe Post-Radiotherapy Complications (n = 818) | No. (%) |
| Total | 251 (30.7%) |
| Hypopituitarism | 126 (15.4%) |
| Hearing Loss | 58 (7.1%) |
| Radiation Necrosis | 30 (3.7%) |
| Cranial Nerve Neuropathies | 14 (1.7%) |
| Osteoradionecrosis | 7 (0.9%) |
| ntracranial Hemorrhage | 4 (0.5%) |
| Memory Loss | 4 (0.5%) |
| Seizure | 4 (0.5%) |
| Brainstem Gliomas | 2 (0.2%) |
| Locoregional Brain Edema | 2 (0.2%) |
| Otitis Media | 2 (0.2%) |
| Convexity Meningioma | 1 (0.1%) |
| Mucositis | 1 (0.1%) |
| Supratentorial Glioblastoma | 1 (0.1%) |
| Symptom Improvement (n = 316) | 138 (46.7%) |
| Radiological Response (n = 247) | No. (%) |
| Reduced tumor volumes | 67 (27.1%) |
| Stable tumor volumes | 144 (58.3%) |
| ncreased tumor volumes | 36 (14.6%) |
| Recurrence (n = 1307) | No. (%) |
| Local Recurrence | 211 (16.1%) |
| Distant Metastases | 7 (0.5%) |
| Treatment for Local Recurrence (n = 211) | No. (%) |
| Surgical resection alone | 33 (15.6%) |
| Radiotherapy alone | 29 (13.7%) |
| Surgical resection + Radiotherapy | 17 (8.1%) |
| Stereotactic radiosurgery alone | 11 (52%) |
| Proton therapy alone | 4 (1.9%) |
| Surgical resection + Stereotactic radiosurgery | 3 (1.4%) |
| Radiotherapy + Carbon therapy | 1 (0.5%) |
| Radiotherapy + Stereotactic radiosurgery | 1 (0.5%) |
| No treatment | 25 (11.8%) |
| Not reported | 87 (41.2%) |
| Outcome (months) | Median, range |
| Follow-up (n = 1307) | 67, 0.1–376 |
| Progression Free Survival (n = 159) | 36, 0.1–300 |
| 5-year rate | 84.3% |
| 10-year rate | 67.4% |
| Overall Survival (n = 233) | 67, 0.1–376 |
| 5-year rate | 94% |
| 10-year rate | 84% |
| Status (n = 1192) | No. (%) |
| Alive | 1058 (88.8%) |
| Dead | 134 (11.2%) |